Dandan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dandan Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chaoyang Zhang
Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Fang Liu
Tenth People's Hospital of Tongji University, Shanghai, 200072, China
1 shared publication - Guo-Tong Xu
Department of Ophthalmology of Tongji Hospital and Laboratory of Clinical and Visual Sciences of Tongji Eye Institute, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Haibin Tian
Department of Ophthalmology of Tongji Hospital and Laboratory of Clinical and Visual Sciences of Tongji Eye Institute, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Jing Wu
Tenth People's Hospital of Tongji University
1 shared publication - Jingfa Zhang
The Primasia International Eye Research Institute, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 10 July 2020
- Published by The Endocrine Society
- Vol. 2020, 1740943
Metformin Protects ARPE-19 Cells from Glyoxal-Induced Oxidative Stress
The protective effects and mechanisms of metformin against oxidative stress were evaluated bothin vivoandin vitro. ARPE-19 cells comprised the normal group, the glyoxal-treated group (0.5 mM glyoxal), and the glyoxal+metformin group (0.5 mM glyoxal and 0.1 mM metformin). In thein vitromodel, differences in cell viability, ROS production, NO products, cellular apoptosis, and the expressions of phospho-AMPK alpha, total-AMPK alpha, Sirt1, Nrf2, TXNIP, ZO-1, and Occludin were assessed. In the glyoxal-treated group, cell viability and NO production were decreased, while ROS production and cell apoptosis were increased (p<0.05), compared with the control group. These changes were prevented by metformin treatment. Protein expressions of phospho-AMPK alpha, Sirt1, TXNIP, ZO-1, and Occludin, but not Nrf2, were decreased significantly in the glyoxal-treated group compared to normal controls. Metformin treatment significantly increased the above protein expressions and slightly increased TXNIP expression. Immunofluorescence showed that metformin prevented the glyoxal-induced, disorganized tight junctions in ARPE-19 cells. To confirm metformin's protection, Sprague-Dawley rats were injected intravenously with sodium iodate (SI) to induce oxidative stress in the retinal pigment epithelium (RPE). Metformin was then delivered intraperitoneally or intravitreally. One day and three days after SI and metformin treatments, the RPE-Bruch's membrane-choriocapillaris complex was isolated and immune-stained with ZO-1 antibodies. The morphology of the RPE showed enlarged cellular bodies and disorganized ZO-1 staining in SI-treated rats. Metformin treatment prevented these changes. The results indicated that metformin maintained the barrier functions of RPE cells bothin vivoandin vitro. Metformin exerted its protection against oxidative stress possibly via activating AMPK/Sirt1 and increasing TXNIP. Metformin has been proposed as a candidate drug for age-related macular degeneration (AMD) by both preclinical and clinical studies. The cellular and animal models used in this study might be useful for the interpretation of the molecular mechanisms involved in the drug activity.
- 10 July 2020
- Published by The Endocrine Society
- Vol. 2020, 1740943
Open AccessMetformin Protects ARPE-19 Cells from Glyoxal-Induced Oxidative Stress
The protective effects and mechanisms of metformin against oxidative stress were evaluated bothin vivoandin vitro. ARPE-19 cells comprised the normal group, the glyoxal-treated group (0.5 mM glyoxal), and the glyoxal+metformin group (0.5 mM glyoxal and 0.1 mM metformin). In thein vitromodel, differences in cell viability, ROS production, NO products, cellular apoptosis, and the expressions of phospho-AMPK alpha, total-AMPK alpha, Sirt1, Nrf2, TXNIP, ZO-1, and Occludin were assessed. In the glyoxal-treated group, cell viability and NO production were decreased, while ROS production and cell apoptosis were increased (p<0.05), compared with the control group. These changes were prevented by metformin treatment. Protein expressions of phospho-AMPK alpha, Sirt1, TXNIP, ZO-1, and Occludin, but not Nrf2, were decreased significantly in the glyoxal-treated group compared to normal controls. Metformin treatment significantly increased the above protein expressions and slightly increased TXNIP expression. Immunofluorescence showed that metformin prevented the glyoxal-induced, disorganized tight junctions in ARPE-19 cells. To confirm metformin's protection, Sprague-Dawley rats were injected intravenously with sodium iodate (SI) to induce oxidative stress in the retinal pigment epithelium (RPE). Metformin was then delivered intraperitoneally or intravitreally. One day and three days after SI and metformin treatments, the RPE-Bruch's membrane-choriocapillaris complex was isolated and immune-stained with ZO-1 antibodies. The morphology of the RPE showed enlarged cellular bodies and disorganized ZO-1 staining in SI-treated rats. Metformin treatment prevented these changes. The results indicated that metformin maintained the barrier functions of RPE cells bothin vivoandin vitro. Metformin exerted its protection against oxidative stress possibly via activating AMPK/Sirt1 and increasing TXNIP. Metformin has been proposed as a candidate drug for age-related macular degeneration (AMD) by both preclinical and clinical studies. The cellular and animal models used in this study might be useful for the interpretation of the molecular mechanisms involved in the drug activity.